吉非替尼治疗老年晚期非小细胞肺癌临床观察

目的观察吉非替尼治疗老年晚期非小细胞肺癌（NSCLC）的疗效及不良反应。方法12例老年晚期无手术及化疗指征的NSCLC患者给予吉非替尼250mg口服，每天1次，直至病情进展或出现不可耐受的不良反应，评价近期疗效、生存期、生活质量及不良反应。结果完全缓解（CR）2例，部分缓解（PR）5例，稳定（SD）3例，进展（PD）2例，有效率为41．67％，临床受益率为58．33％；中位无疾进展时间为6个月，中位生存期为13个月，1年生存率为63．23％；生活质量明显改善者占66．67％；药物不良反应多为Ⅰ～Ⅱ度皮疹及腹泻。结论吉非替尼应用于老年晚期不能手术和化疗的NSCLC患者的治疗，疗效确切，不良反应轻微，可明显改善患者的生活质量。

Clinical observation of gefitinib treatment of elderly advanced non-small cell lung cancer

Objective To observe the efficacy and adverse reaction of gefitinib treatment of elderly advanced nonsmall cell lung cancer（NSCLC）. Methods 12 elderly patients without surgery and chemotherapy with advanced NSCLC were given with gefitinib 250mg once daily orally until disease progression or they could not be tolerated adverse reaction, evaluated short-term effect, survival, quality of life and drugs sied effects. Results CR 3 cases, PR 5 cases, SD 3 cases, PD 2 cases, effeciency was 41.67% ,clnical benefit rate of 58.33%, median progression-free time for 6 months,with a median survival time was 12 months, 1 year survival rate was 63.23%, significant improvement in the quality of life accounted for 66.67% ;Adverse drug reactions,mostly was Ⅰ - Ⅱskin rash and diarrhea. Conclusion Gefitinib can be used in elderly patients with advanced NSCLC surgery and chemotherapy for the treatment of curative effect, adverse reactions are mild, but can significantly improve patient quality of life survival.